MLL-AF4 fusion is the most common consequence of chromosomal translocations in infant leukaemia and is associated with a poor prognosis. MLL-AF4 is thought to be required in haematopoietic stem cells to elicit leukaemia and may be involved in tumour phenotype specification as it is only found in B-cell tumours in humans. We have employed the invertor conditional technology to create a model of MLL-AF4, in which a floxed AF4 cDNA was knocked into Mll in the opposite orientation for transcription. Cell-specific Cre expression was used to generate Mll-AF4 expression. The mice develop exclusively B-cell lineage neoplasias, whether the Cre gene was controlled by B-or T-cell promoters, but of a more mature phenotype than normally observed in childhood leukaemia. These findings show that the MLL-AF4 fusion protein does not have a mandatory role in multi-potent haematopoietic stem cells to cause cancer and indicates that MLL-AF4 has an instructive function in the phenotype of the tumour.
Introduction
Tumourigenesis of leukaemias and lymphomas, of sarcomas and more rarely of epithelial tumours involves the generation of chromosomal translocations, probably as initiating events in cancer formation (Rabbitts, 1994) . In the former, the translocations are generally reciprocal resulting in two derivative chromosomes, both of which are usually present in the tumour cells at the time of presentation. Gene fusion is the most common effect of chromosomal translocations. Different tumour types are usually associated with different, recurrent gene fusions in haematopoietic tumours and in sarcomas. Those in acute leukaemias tend to involve transcription regulators (Cleary, 1991; Rabbitts, 1991) whose role in cell fate is akin to master regulators determining a developmental effect on the afflicted cell (Rabbitts, 1991) . In addition, the type of translocation typically found in one tumour subtype can be a valuable prognostic indicator. The MLL gene on human chromosome 11, band q23, is one of the most frequently involved genes in chromosomal rearrangements, being particularly common in childhood leukaemia. There are more than 40 genes described as MLL partner genes (reviewed by Daser and Rabbitts, 2004) , and the three most common partners give rise to MLL-AF4 (MLL-MLLT2), MLL-AF9 (MLL-MLLT3) and MLL-ENL (MLL-MLLT1) fusions. These three fusions account for over 60% of leukaemia with 11q23 abnormalities. The cell-type specificity of translocation-associated gene fusions is well illustrated by the MLL translocations. MLL-AF4 translocation is almost exclusively found in B-cell acute lymphoblastic leukemia (ALL), while MLL-AF9 is predominantly in acute myeloid leukaemia (AML), and MLL-ENL fusion has been described in both. This tumour tropism raises the question whether expression of the particular translocation product can only promote clonal proliferation in a particular cellular context or whether the fusion product has direct effects on the differentiation (non-instructive vs instructive models of MLL-mediated leukemogenesis (Rabbitts, 1991) ).
The chromosomal translocation of MLL invariably results in the replacement of the C-terminal domains, including the SET domain, with a fusion partner, thereby losing the histone H3 lysine 4 methyltransferase function, affecting the ability to recruit proteins to the MLL multi-protein complex (Daser and Rabbitts, 2004) . The molecular basis for the MLL-fusionmediated transformation of haematopoietic cells has been extensively studied in several cases but the functional consequence of MLL-AF4 fusion has not been elucidated, in part due to the lack of mouse models of the fusion. Two main pathogenic mechanisms have been suggested by experimental studies of various other MLL fusions. The first is transcriptional activation properties conferred by fusion partners (e.g. AF10, AFX, CBP, ENL, ELL) (Rubnitz et al., 1994; Slany et al., 1998; DiMartino et al., 2000 DiMartino et al., , 2002 Lavau et al., 2000) or the second is dimerization properties conferred on the fusion molecule that are an important component of tumourigenicity (Dobson et al., 2000; Martin et al., 2003; So et al., 2003) .
The poor clinical outcome and lack of understanding of MLL-AF4 biology prompted our attempts to generate a mouse model. We have used a recently developed conditional knock-in technique termed the invertor method as a chromosomal translocation mimic strategy to generate an Mll-AF4 fusion. The invertor conditional knock-in method depends on the insertion of a floxed invertor cassette into the intron of a target gene, by homologous recombination in embrynonic stem (ES) cells, such that the cassette is in the opposite orientation for transcription to the target gene until inverted by Cre recombinase. Mll-AF4 invertor mice develop late-onset lymphoid tumours with high incidence. Expression of the Mll-AF4 fusion gene in different cell types by expressing Cre recombinase under the control of Rag, Lck or CD19 promoters resulted in diffuse large B-cell lymphomas. We therefore conclude that Mll-AF4 is oncogenic in committed cells of the lymphoid lineage and does not have to be expressed from the haematopoietic stem cells. Long latency and presence of clonal Igh rearrangements in the majority of cases suggest that the B-cell neoplasias are clonal and the Mll-AF4 fusion is necessary but not sufficient for cancer in this model.
Results

Mll-AF4 fusion is lethal for mouse embryos
We initially used the knock-in approach to produce an MLL-AF4 mouse model analogous to the method used for the Mll-AF9 knock-in (Corral et al., 1996; Dobson et al., 1999 ). An AF4 cDNA-polyA cassette was fused into exon 10 of the mouse Mll gene in ES cells (see Figure 1 Invertor strategy for generating Mll-AF4 mice. Invertor Mll-AF4 was made as described previously Forster et al., 2005) with a human AF4 cDNA sequence. (a) Diagram of part of the mouse Mll gene and of the AF4 invertor cassette. A partial restriction map of mouse Mll around exons 8-10 is shown in the top line, indicating the BglII site into which the AF4 invertor cassettes were introduced. Probes located 5 0 and 3 0 of the respective Mll fragment (Mll 5 0 probe, Mll 3 0 probe). The invertor cassette is depicted below the Mll map and two forms were used, one flanked by wild-type loxP sequences (loxP) and a second generation by the mutant loxP sites (lox66 and lox71 (Albert et al., 1995) ). These sequences are shown below the AF4 invertor cassette. (b and c) Organization of the targeted Mll-AF4 invertor allele before and after Cre mediated inversion of the cassette. Primers located in Mll exon 10 (MEF), Af4 intron 4 (AIR, fluorescence labelled), and AF4 exon 5 (AER) are indicated by red arrows. The genomic fusion sequence was amplified using primers MEF and AIR. Primer AIR was labelled with 5 0 fluorescein to quantify the inversion efficiency and Cre specificity by competitive polymerase chain reaction (PCR) (see Figure 3e ). Primers MEF and AER were used for reverse transcription (RT)-PCR (RT) to amplify and sequence the expressed fusion mRNA. (d) Mll-AF4 fusion transcript and derived protein sequence (written in single letter code) obtained from spleen RNA from Mll-AF4 lox; Cre mice. (e) Fusion transcript and derived protein sequences of Mll-AF4 lox66/71; Cre invertor. Note that the exact sequence at the junction of Mll and AF4 in the two forms of invertor mice differ slightly due to splice variation. Sp, SphI; Xb, XbaI; R, EcoRI; H, HindIII; K, KpnI; Bg, BglII; B, BamHI. chr. ¼ chromosome.
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Supplementary Figure 1a) . Expression of the Mll-AF4 fusion transcript could be demonstrated in these knockin ES cells (Supplementary Figure 1c shows the junction sequence of the fusion mRNA). However, injection of two different clones of targeted ES failed to yield chimaeric mice (Supplementary Figure 1b) . In an attempt to circumvent this embryonic lethal effect, a conditional knock-in version was generated using a floxed transcription stop (Mll-AF4 loxP-stop) analogous to that described for Aml-Eto fusion (Higuchi et al., 2002) (Supplementary Figure 1a) . Like the Mll-AF4 fusion knock-in, we were unable to produce chimaeric mice with the Mll-AF4 loxP-stop ES cells (Supplementary Figure 1b) . We concluded that transcriptional read through of the loxP-STOP allowed the embryonic lethal effect of the Mll-AF4 fusion transcript.
We have recently designed a conditional knock-in model (the invertor method) based on gene targeting of an inverted cDNA floxed cassette comprising a short intron, acceptor splice site, a cDNA segment and a polyadenylation (pA) sequence. In this invertor model the initial gene targeting precludes fusion mRNA production by the inverse transcription orientation of the introduced cassette . Mll-AF4 invertor ES cells were created, injected into blastocysts and germline carriers of the cassette were made. This Mll-AF4 knock-in model was not subject to embryonic lethality, allowing inter-breeding with lines of mice expressing Cre recombinase in various specific haematopoietic cell types. Two sets of Mll-AF4 invertor ES cells were made in which the AF4 cassette was flanked by either wild-type or mutant loxP sites (Hoess et al., 1982; Albert et al., 1995) (Mll-AF4 loxP and Mll-AF4 lox66/71 invertors, Figure 1a ). Following expression of Cre recombinase in the ES cells, the invertor cassette knocked-in to Mll intron 10 ( Figure 1b ) became inverted and thus was orientated in the same transcriptional direction to Mll (Figure 1c ) and was transcribed into a fusion mRNA of Mll-AF4 (Figure 1d and e).
Mll-AF4 invertor mice develop lymphoid tumours Targeted ES cells were used to make Mll-AF4 invertor mice that were crossed with mice expressing Cre recombinase under control of the lymphocyte-specific promoters of Rag, Lck and CD19 to generate cohorts that were observed for a period of 18 months (we were unable to generate Mll-AF4 invertor mice crossed with Lmo2-Cre (Nam and Rabbitts, 2006) due to embryonic lethality similar to Mll-AF4 knock-in, unpublished). High proportions of these mice developed lymphoid tumours in this period, ranging from B70 to 90%. Survival curves are shown in Figure 2 for the six groups of mice studied, demonstrating a similar time course of disease incidence irrespective of the Cre strain of mice used to invert the AF4 cassette into the Mll-AF4 fusion mRNA. Survival data for all invertor strains showed highly significant differences from wild-type Mll; Cre controls (Po0.0001). The log-rank P-value for the comparison of Mll-AF4 loxP; Rag-Cre with Mll-AF4 lox66/71; Rag-Cre survival was 0.012.
Prominent findings in the post-mortem examinations were extreme splenomegaly and mesenteric lymphadenopathy due to infiltration by lymphoma. Macroscopic infiltration of lymphoma into liver and kidney was only seen in late-stage disease. The thymus was often slightly enlarged and discrimination from mediastinal lymph nodes was not always possible. Lymphomas were not Figure 2 Mll-AF4 invertor mice develop haematopoietic malignancy Survival curves of Mll-AF4 invertor mice. Cohorts of MllAF4lox; Cre mice and controls lacking either the invertor or Cre alleles were established and post-mortem examinations carried out at signs of ill health. Latency and frequency of disease is plotted for invertor mice with Cre recombinase expression under the control of either the Rag1, Lck and CD19 promoters . Incidence of lymphoid tumours was 31/36 mice (86%) for Mll-AF4 loxP; Rag-Cre; 25/29 (86%) for Mll-AF4 lox66/71; RagCre with a median latency of 466 and 317 days, respectively. Incidence was 11/12 mice (92%, mean latency 416 days) for Mll-AF4 loxP; Lck-Cre and 17/18 (94%, mean latency 472 days) for Mll-AF4 lox66/71; Lck-Cre. Incidence was 6/7 mice (86%, mean latency 475 days) for Mll-AF4 loxP; CD19-Cre mice and 10/14 (71%, mean latency 460 days) Mll-AF4 lox66/71; CD19-Cre mice. Survival curves of all invertor strains were highly significant compared to the corresponding Mll-wt; Cre controls (Po0.0001). The Mll-AF4 loxP; Rag-Cre strain differs from Mll-AF4 lox66/71; Rag-Cre cohort with a log-rank P-value of 0.012. Black lines represent Mll-AF4 lox66/71 strains, grey lines Mll-AF4 loxP strains and dashed lines Mll wt; Cre strains.
usually found in other sites. Blood smears of tumourbearing mice showed no striking abnormalities compared to wild-type animals. The number of circulating white blood cells was usually only slightly increased (WBC 4.872.8 vs 3.572.0), while the red blood cell and platelet numbers were slightly reduced (RBC 7.671.3 vs 9.870.5; PLT 893.67387.0 vs 1095.17378.2). In differential WBC counts, granulocyte and monocyte numbers were moderately increased (lymphocytes 1.570.8 vs 1.771.0; monocytes 0.770.4 vs 0.470.2; granulocytes 2.771.6 vs 1.471.1).
Mll-AF4 fusion transcript is present in lymphomas Tumour incidence in the Mll-AF4 cohorts was dependent on the Cre-expression allele (Figure 2 ) but there was only a significant difference in time of onset of tumourigenesis between mice with the invertor cassette flanked by wild-type or mutant alleles loxP in the case of the Rag-Cre mice. Filter hybridization analysis of genomic DNA was used to establish the occurrence of AF4 inversion in spleen, thymus, lymph node, liver and kidney (tail biopsy DNA was used as control to show the germline and knock-in Mll alleles) of mice that succumbed to lymphoma. The inverted segment was readily detected in spleen, thymus and lymph node and the intensity of the inverted allele correlated with the level of tumour infiltration in the respective tissues (Figure 3a and c).
Transcription of the resulting Mll-AF4 fusion gene was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) with primers positioned in exon 10 of Mll and exon 5 of AF4 (Figure 3b and d, and Supplementary Figure 2 ). After inversion of the AF4 cassette, chimaeric mRNA is transcribed and spliced to give Mll-AF4 fusion mRNA representative of the fusion product found in human leukaemia. Owing to higher sensitivity of RT-PCR compared to filter hybridization, fusion transcript was also detected in low-grade infiltrated tissues such as the liver and kidney. The RT-PCR products were cloned and sequenced to demonstrate the in-frame fusion of Mll and AF4 exons as shown for transcripts in the targeted ES cells ( Figure  1d and e).
Specific Cre expression in defined haematopoietic populations (spleen, thymus and bone marrow) has been demonstrated previously using a highly sensitive reporter assay for Cre-mediated deletion . In brief, Rag1-Cre is highly expressed in both, B-and T-progenitor subsets, but is not detectable in Mac1 þ cells. Lck-Cre is exclusively expressed in the T-cell compartment from the DN1 stage onwards. There was no evidence of Cre activity in cells sorted for the expression of CD34, Sca1, Ter119, Mac-1 or Gr-1. Further, no Cre activity could be detected after selection of cells expressing B-cell markers (CD19, B220, immunoglobulin (Ig)M, IgD or IgG). These results with Lck-Cre were confirmed by flow cytometry using the ROSA-YFP lox-STOP deletion (Srinivas et al., 2001 ) as a fluorescent gene reporter assay (L Drynan and THR unpublished). CD19-Cre expression is limited to B cells, (Figure 3e ). Mll-AF4 lox66/71; Rag-Cre mice showed inversion of about 65% unsorted spleen cells, whereas in the Mac1 þ fraction inverted alleles were only found at low frequency, attributable to the level of contaminating lymphocytes in the sorted populations. Inversion was induced almost equally in B220 þ and Thy1.2 þ cells. By contrast, Mll-AF4 lox66/ 71; Lck-Cre mice showed inversion exclusively in Thy1.2 þ cells. Efficiency of inversion was higher than in Mll-AF4 lox66/71; CD19 mice, in which Cre expression was tightly restricted to B220 þ lymphocytes.
Mll-AF4 invertors develop diffuse large B-cell lymphoma
The post-mortem examination of the three types of invertor mice showed these animals all developed lymphoid neoplasms. Histology and immunohistochemistry identified the tumours, by the Bethesda classification (Morse et al., 2002) , uniformly as diffuse large cell lymphoma of the centroblastic subtype, typically involving spleen, thymus, and mesenteric lymph nodes, although some mice had only splenomegaly, without mesenteric lymph node enlargement. The infiltration of non-lymphatic organs such as liver and kidney was more variable and dependent on the stage of disease at the time of post-mortem examination (Figure 4a ). Bone marrow was rarely affected. Enlarged mesenteric lymph nodes were full of lymphoid cells (demonstrated for one representative mesenteric lymphoma in Figure 4a ), that could be identified as B cells by their staining with the anti-B220 B-cell marker (Figure 4a ). The lymphoma cells were characterized by their large vesicular nuclei, clumping chromatin, and 1-5 prominent nucleoli. Numerous mitoses and many apoptotic cells were present in tumour areas (Figure 4b , top row).
Immunohistochemistry was used to demonstrate the B-cell phenotype of the lymphoma cells (Figure 4b , second row). These were large B-cell centroblastic lymphomas (DLBCL) and typically, were infiltrated by small reactive T cells to some level (Figure 4b , third row). Myeloid cells were absent in tumour areas, as judged by the absence of cells expressing the F4/80 myeloid marker in the lymphomas ( Figure 4b , bottom row; as a control the spleen red pulp stained with this antibody, insets). In a minority of tumours, small areas of histiocytic infiltrates were observed in a pattern compatible with histiocytic subtype of DLBCL. There were no differences between Rag, Lck or CD19-Creexpressing mice in respect of lymphoma morphology and immunophenotype. A summary of histology results is shown in Supplementary Table 1 online.
The B-cell phenotype of the Mll-AF4 invertor tumours was confirmed by studying the status of the immunoglobulin heavy chain and T-cell receptor genes. Overall, about 60% of the lymphoma-infiltrated spleens or lymph nodes analysed showed clonal Igh rearrangements of at least one allele (Figure 5a and d) . The remaining germline band originated from residual normal cells or reactive T cells in spleens, which were only partially replaced by lymphoma cells or reactive Figure 5d .
Since a restricted B-cell phenotype was observed in the Mll-AF4 invertor tumours independently of the promoter controlling expression of the Cre, we have investigated possible alterations in haematopoietic profiles prior to overt disease. The surface protein expression of leukocytes from spleen and thymus of asymptomatic Mll-AF4 mice of each Cre-expressing line was analysed at the age of 7-9 months using flow cytometry. No significant differences were found compared with Cre-only expressors or C57BL/6 wild-type mice ( Supplementary Figure 3a and b) . We further investigated possible perturbations of T-cell development in Mll-AF4; Lck-Cre mice by assessing T-cell help for immunoglobulin production. Mice were immunized with TNP-OVA and serum IgG was quantitated at 2 and 4 weeks. However, no differences were seen in the invertor mice compared with Cre-only controls (Supplementary Figure 3d ) suggesting that gross changes to T h cell function had not occurred, as expected from the normal numbers of CD4 þ T cells.
Since the B-cell tumour phenotype was identical for all three different Mll-AF4 invertor strains, we compared the RNA expression profiles to gain insights into possible variance due to the cancer stem cell of tumour origin. Reverse transcription-polymerase chain reaction ( Figure 6d ) and micro-array analysis were performed on spleen RNA from transplanted Mll-AF4 lox66/7; LckCre and from Mll-AF4 lox66/7; CD19-Cre tumours (Supplementary Table 2 ) compared with RNA made from Rag1À/À spleen which lack lymphocytes and comprise >90% Mac1 þ /Gr-1 þ myeloid cells (data not shown). The overall expression pattern highlighted the close similarity of tumours from both groups. B-cell differentiation markers, like Pax5 and Ebf are robustly expressed as expected from the B-cell phenotype of the tumours. Examination of the expression profiles by either micro-array analysis or by RT-PCR (Figure 6d and Supplementary Figure 4 online) shows that the major Mll-fusion target genes like Hoxa9 or Meis1 are expressed in the B-cell tumours.
A subset of genes with differential expression in Mll-AF4 lox66/7; Lck-Cre compared to Mll-AF4 lox66/7; CD19-Cre lymphoma was found (Supplementary Table  2 , online) and of special interest is two of the differentially expressed genes, Bcl6 and the antiapoptotic oncogene Bcl2. Both have been identified as significant class discriminating genes for distinct subtypes of human DLBCL in molecular classification studies (Alizadeh et al., 2001; Wright et al., 2003) . Whereas BCL6 was found to be overexpressed in the GC B-like DLBCL signature, Bcl2 expression was more than four times higher in activated B-like DLBCL compared to GC B-like DLBCL. Bcl2 is normally downregulated in the GC where apoptosis plays a critical role in negative B-cell selection. Bcl6 was expressed at lower levels in Mll-AF4 lox66/71; Lck-Cre lymphoma samples than in similar CD19-Cre samples, (Figure 6a and b, top rows) . The tumours that arose in the Rag1À/À recipients (within an average of 2 months) were examined and FACS analysis showed that there had been expansion of only the lymphomatous B cells and very few T and myeloid cells remained (Figure 6a and b, middle rows; 1st Rag1À/À). Transfer of these splenic tumour cells into secondary Rag1À/À recipients gave rise to tumours within 17-23 days (four of four recipients) and the surface marker phenotype was explicitly that of a B-cell neoplasm (Figure 6a and b, bottom rows). A transplanted tumour arose in the recipient Rag1À/À mice transplanted with cells from an Mll-AF4; Rag1-Cre invertor tumour and was exemplified by splenomegaly and extensive infiltration of liver and kidneys. Fluorescence-activated cell sorter analysis showed a similar B-cell phenotype to those in the CD19-Cre and Lck-Cre invertor transplant experiments (data not shown). The correspondence of the primary tumour from the Mll-AF4 lox66/71; CD19-Cre donor mouse with that of the transplanted tumours in the Rag1À/À recipients was investigated by analysis of clonal Igh gene rearrangement (Figure 6c) . Filter hybridization showed a faint band corresponding to clonal rearranged Igh allele in the DNA from the invertor tumour from lymph node Figure 6 Mll-AF4 invertor tumours are transplantable in Rag1 null mice. Single-cell suspensions were made from spleens of Mll-AF4 lox66/71; CD19-Cre or Mll-AF4; Lck-Cre tumour mice or mesenteric lymphoma of the Mll-AF4 lox66/71; CD19-Cre mouse and 5 Â 10 6 cells injected into the tail vein of a Rag1À/À mouse. A massive lymphoma infiltration of spleen and mesenteric lymph nodes as well as liver and kidneys of the first recipient mouse occurred within 7 and 11 weeks, respectively. The spleens of these mice were used as a source of cells for flow cytometric analysis, DNA preparation and re-transplantation into four secondary Rag1À/À recipients. The latter developed tumours after 17-23 days and the spleens from these mice were taken for analysis. 
Discussion
Mouse models of MLL-AF4 fusion Mouse models of human MLL-associated leukaemia have been generated to evaluate the oncogenicity of numerous MLL-fusion proteins in different cells of haematopoiesis using knock-in techniques, translocator mice, and retroviral transduction (reviewed by Daser and Rabbitts, 2004) . Translocator mice are closest to natural chromosomal translocations in human cancers, as both derivative chromosomes of the translocator mice are created somatically by Cre-loxP recombination . The translocator strategy depends on the identical orientation of both targeted genes on the relevant mouse chromosomes to generate 5 0 -3 0 exon fusion following translocation. Unlike the human orthologue, the transcriptional orientation of Mll and Af4 in mice appears to be in opposite directions, which would result in dicentric chromosomes in the translocator model (G Testa, F Stewart, AF, RP, MM, AD and THR unpublished). Therefore, a different approach was needed. A fully conditional model was developed in which a knock-in cassette is converted into the correct transcriptional orientation by Cre recombinasemediated inversion at loxP sites . We applied this method to the Mll-AF4 fusion model.
Our invertor technology provides the first generation of B-cell-specific models for MLL-AF4, albeit of a more mature phenotype than usually found in human leukaemia. This should be a valuable addition to the repertoire of MLL models allowing studies of secondary mutations cooperating with MLL fusions, lineagespecific target genes and an important element to development of new therapies to target MLL leukaemia. This last point is of particular clinical relevance as the prognosis of MLL-AF4 associated leukaemia is very poor, especially if it occurs before 1 year of age (Pui et al., 2002) and new drugs are needed to treat this leukaemia.
B-cell tumours in Mll-AF4 invertor mice
We used three distinct lines of Cre expressing mice to facilitate the inversion of the AF4 cassette and identical lymphomas occurred in all three situations with high penetrance. A long latency period was observed in all three and little difference was found when the invertor cassette was flanked by wild-type loxP sites or the mutant loxP sites, except for the Mll-AF4; Rag-Cre in which the mutant loxP allele increases the rate of tumour formation somewhat. The original rationale of using mutant loxP sites was to favour the forward reaction, which should result in a higher number of alleles with correct transcriptional orientation. The probable reason for the lack of disparity between wildtype and mutant loxP sites is that, at the single-cell level, the longevity of Mll-AF4 mRNA and protein allows for continued phenotype even when the allele has reinverted. The long latency suggests that expression of the fusion transcript alone is not sufficient for overt lymphoma. This interpretation is supported by the detection of clonal Igh rearrangements in 60% of the cases. As Cre-mediated inversion and expression of the Mll-AF4 chimaeric mRNA will occur in a large number of cells, oligo-or polyclonal tumours with diverse immunoglobulin gene rearrangements might be expected to occur. At present, we have not been able to identify any secondary mutations that might be responsible for overt growth of the invertor mouse tumours. Mutations of the FLT3 gene occurs in a proportion of human MLL-associated tumours (Christiansen and Pedersen-Bjergaard, 2001; Jamal et al., 2001 ) but none were found (direct sequencing of the Flt3 activation loop coding region showed no base changes in 12 tumours analysed; no internal tandem duplications were detected in 51 primary tumours, data not shown). Further, we have thus far found no evidence of Cmyc-associated chromosomal translocations in the invertors.
Cellular origin of Mll-AF4 leukaemias
Our results demonstrate two features of MLL-AF4 biology. First that the stem cell in which the fusion is expressed does not have to be an uncommitted progenitor to elicit lymphoid neoplasia and second that MLL-AF4 influences the phenotype of the tumour when expressed within cells of the lymphoid lineage. In infant MLL-AF4-positive leukaemia, the tumours typically show the phenotype of the B-lymphocyte lineage, mainly immature pre/pro-B-cell leukaemias. The tumours in the Mll-AF4 invertor mice were always more mature B cells (Supplementary Table 1 ). This difference may reflect the timing with which the Mll-AF4 fusion is available to induce neoplasia. There is a high percentage of patients with t(4;11) translocations without clonal immunoglobulin heavy chain and T-cell receptor gene rearrangements suggesting that an immature progenitor cell is the target of the chromosomal translocation (Peham et al., 2002) . However, characterization of sorted cells from leukemic bone marrow of childhood high-risk ALL/ t(4;11) suggested an origin in a primitive lymphoidrestricted progenitor cell (Hotfilder et al., 2005) . Moreover, studies in monozygotic twins with leukaemia, carrying an identical MLL-AF4 chromosomal translocation, but different immunoglobulin rearrangements strongly supported the model that the primary MLL-AF4 target cell was a progenitor cell at a differentiation stage before efficient RAG expression (Mori et al., 2002; Greaves et al., 2003) . This issue could be addressed using the Mll-AF4 invertor model and an inducible Cre driven by a promoter of a gene, such as Lmo2, expressed in bone marrow progenitor cells.
The expression data are an indicator of the mechanism by which MllAf4 fusion (which is necessary but not sufficient to cause tumours in this model) contributes to tumourigenesis. While the normal MLL-AF4 target genes are expressed at moderate levels, the lack of high expression suggests that lineage restriction requires these gene to be activated by Mll-AF4, the clonal tumours develop to overt cancer via activation of additional sets of genes, together with additional mutations in as yet undetermined genes (although our data make the Flt3 gene an unlikely target). More complex mouse models will be required to dissect these functional requirements which should yield indicators important indicators for therapeutic strategies. The expression data highlight features of the mechanism of Mll-AF4 invertor tumourigenesis. The Mll-fusion target genes Hoxa9 or Meis1 are continued to be expressed in the B cell tumours. Meis1 expression appears to be similar to the myeloid cells of a Rag1À/À spleen and thus the Mll-AF4 protein would appear to be activating this gene, even in the Bcell lymphomas. Meis1 is a commonly expressed MLLfusion target gene and is an important cofactor for myeloid differentiation (Nakamura et al., 1996; Chang et al., 1997) . B-cell tumourigenesis may occur in the invertor model by a mechanism that initially requires Meis1 (and Hoxa9) expression but not at the later stage of the DLBCL development, where the mutation of other genes must play a role since this marker is essentially undetectable from this tumour type in humans (Shipp et al., 2002) .
The micro-array data show that IgM is prominently expressed in the Mll-AF4; Lck-Cre tumours, compared with Mll-AF4; CD19-Cre mice suggesting that, while the phenotype of these tumours is dependent on Mll-AF4 function, transformation to overt neoplasias occurs in B cells that have not yet undergone immunoglobulin class switch. Expression of Bcl6 was found in both Mll-AF4; Lck-Cre and Mll-AF4; CD19-Cre mice but not at high levels, compared with control, unfractionated spleen RNA. Mll-AF4; Lck-Cre mice have relatively high expression the antiapoptotic gene Bcl2 compared to Bcl6, and this may cause a pausing of the cells at the early stages of B-cell development. The fact that Mll-AF4; Lck-Cre mice always display diffuse large cell lymphoma is further evidence that in the mouse model, Mll-AF4 fusion protein function by-passes the equivalent early B-cell progenitor stage. Lck itself remains highly expressed in the tumours derived from Mll-AF4; Lck-Cre mice (Figure 6d ) which points to an instructive mechanism for Mll-AF4 fusion in these mice, contributing to lineage commitment from very early Lck þ T-cell progenitors, still capable of differentiating into other cell types. Retention of Lck expression is a footprint of the non-committed T-cell progenitors. The tumours in the Rag-Cre invertors were all of the B-cell type, even though Rag1-Cre is expressed in both B and T cells and T-cell lymphomas can arise from an Ews-ERG invertor model Forster et al., 2005) at least suggesting that Mll-AF4 is not a T-cell oncogene.
Our data show that Mll-AF4 fusion can be oncogenic in cells restricted to the lymphoid lineage (i.e. not only in uncommitted progenitors). The resultant tumours are transplantable and can infiltrate primary and secondary host tissue aggressively. All the lymphomas showed an identical phenotype, even Mll-AF4; Lck-Cre mice. Previous data showed that the Lck-Cre expression is tightly restricted to cells in the T-cell developmental pathway from the DN1 stage onwards . Recently, using the translocator mouse model in which Cre-dependent de novo chromosomal translocations occur, we have shown that the Mll-Enl fusion can cause lineage reassignment from T cell to the myeloid cell lineage . This may occur if the translocation occurs within a restricted target cell representing a non-committed T-cell precursor whose cell fate would normally be to differentiate into Tcr-expressing thymocytes and then to become a functional, mature T-cell. The Mll-fusion protein subverts this normal course of events. The intriguing possibility is that the expression of Mll-Af4 in this postulated non-committed T-cell progenitor could also cause reassignment of the lineage, in this case to the B-cell lineage. While the examination of such developmental alteration by the Mll-Af4 fusion is outside the scope of the current establishment of a tumour system, second-generation models should be able to address this question using Cre-expressing mice with the capability to cause AF4 inversion at precisely defined times in haematopoiesis.
Materials and methods
Generation and characterization of Mll-AF4 invertor mice
The AF4 cDNA segment from nt 1504 to 4304 (AccNo. NM_005935) was amplified from a human B-ALL sample RNA and cloned into the NotI site of pC2-neo . The entire fragment from the clone (AF4-pA-MC1Neo-pA) was excised as an Sfi1 fragment, the restriction site ends filled in and the fragment was introduced into the blunted BamHI site of pLOXKI so that the AF4-pA-MC1Neo-pA sequences were immediately downstream of the short intron sequence and acceptor splice site in pLOXKI and all flanked by loxP sites (to give pLOXKI-AF4). The invertor cassette of pLOXKI-AF4 was cloned as a SceI-ClaI blunt fragment into the blunt-ended BglII site of the Mlltargeting vector (a 5.5 kb EcoRI fragment (Collins et al., 2000) ). Finally the Herpes simplex virus (HSV) tk gene was added as a blunt end filled XbaI fragment into the blunted ClaI site of the Mll-targeting vector. For electroporation into CCB ES cells, the final construct was linearized with XhoI.
For the Mll-AF4 lox66/71 version, a vector designated pLOXKI2 was constructed. The lox66 sequence was introduced as oligonucleotides into SacII-NotI-digested pMG2 followed by the short segment of the Af4 intron as an XbaI-BamHI PCR fragment. The lox71 site was cloned as oligonucleotides into the EcoRV-HindIII sites to give pLOXKI2 (analogous to pLOXKI ). The AF4 cDNA fragment was cloned as a blunt Sfi1-NotI into the blunt BamHI site of pLOXKI2 and the SV40pA-MC1-neopA fragment was blunt end cloned into the polylinker EcoRV site to yield pLOXKI2-AF4. This invertor cassette was cloned as a SceI-ClaI blunt fragment into the blunt-ended BglII site of the genomic Mll EcoRI fragment-targeting vector. The HSV tk gene was added as a blunt XbaI fragment into the blunt ClaI site of the Mll targeting vector and linearized with XhoI.
C57BL/6 mice carrying Mll-AF4 loxP or Mll-AF4 lox66/71 alleles were bred with those expressing Cre recombinase under the control of the Rag1, Lck, or CD19 promoter . Animals were culled at the first signs of ill health. Log-rank test was used to determine significant differences of survival curves. Blood smears were stained with MayGru¨nwald-Giemsa (MGG) stain and an automated differential blood count from ethylenediaminetetraacetic acid-blood was carried out (Animal Blood Counter, Vet abc, HORIBA ABX, Montpellier, France). Sections (4 mm) of paraffinembedded tissues were stained with haematoxylin and eosin.
Tissue sections for immunohistochemistry were dried overnight at 601C and subsequently deparaffinized in xylene, dehydrated in ethanol, and washed in water. Antigen retrieval was accomplished by placing slides in a pressure cooker at full pressure for 3 min in 0.01 M citric acid, pH 6.0. Sections were stained using a Dako TechMate 500 automated immunostainer (Dako, Glostrup, Denmark) with a primary (rat antimouse B220 (BD Pharmingen, Franklin Lakes, USA; 1/25 dilution), CD3 (Dako; 1/50 dilution), and F4/80 (Serotec Ltd., Oxford, UK; 1/50 dilution)) antibody incubation time of 45 min and a standard biotinylated secondary (goat anti-rat; 1/250 dilution) antibody for 30 min and a streptavidin tertiary complex for 30 min with a diaminobenzidine (DAB) visualization system. Sections were counterstained with Mayer's haematoxylin, for a blue nuclear contrast to the DAB-derived brown immunopositive end product.
Filter hybridization of SphI-digested genomic DNA from various tissues was carried out using the Mll 5 0 probe (Collins et al., 2000) (Figure 1a ) to detect the inverted allele in the various organs. To estimate the proportion of inverted vs noninverted Mll-AF4 alleles in various cell populations, DNA was prepared (Qiagen Blood Kit, Qiagen, Hilden, Germany) from 10 000 unsorted or FACS-sorted cells expressing Mac-1, B220 or Thy1.2 Purity of the sorted populations was X97.5%. 1/10 of the DNA solution, primer MEF, the fluorescent primer AIR, and a primer set for the single copy gene Lmo2 were used in a PCR reaction with the following conditions: 941C 10 min, 35 cycles each of 941C 30 s, 661C 30 s, 721C 60 s and final extension at 721C 7 min. PCR products were separated by capillary electrophoresis (ABI Prism 3100 Genetic Analyzer; Applied Biosystems, Foster City, USA), quantified by calculation of the area under the curve (Genescan Analysis Software, Applied Biosystems), and the ratios of inverted allele/Lmo2 allele were calculated.
Total RNA was extracted from tissues or sorted cells by Trizol reagent (Invitrogen, Paisley, UK), digested with RNasefree DNAse (Qiagen) and purified by RNeasy columns (Qiagen). cDNA was synthesized with random nonamer primers and 100 ng of cDNA was amplified in a PCR using primer sets positioned in Mll exon 10 and AF4 exon 5 ( Figure  1b and c, sequences in Supplementary Figure 2a and b) . Polymerase chain reaction products were visualized on 2% agarose gels stained with ethidium bromide.
Flow cytometric analysis of cell surface marker expression Single-cell suspensions were prepared from mouse thymus, spleen, lymph node and bone marrow. Cells were stained with either fluorescein isothiocyanate-, phycoerythrin-or allophycocyanin (APC)-conjugated antibodies to CD4, CD8, Thy1.2, CD25, CD44, Gr-1 (Ly-6G), Mac-1 (CD11b), B220 (CD45R), IgM, IgD, CD138, CD43, CD24, c-kit, Sca-1, and CD34, or matching isotope control antibodies (BD Pharmingen) and analysed using a FACSCalibur flow cytometer and Cell Quest software (BD, Franklin Lakes, USA).
Cell transplantation into Rag1À/À recipients Single cell suspensions of tumour cells from infiltrated spleens or mesenteric lymph nodes were purified by density gradient centrifugation and injected intravenously at a dose of 5 Â 10 6 cells into Rag1À/À mice (Mombaerts et al., 1992) . Recipients were monitored and sacrificed at the first signs of lymphoma. Tissues were tested for the presence of Igh rearrangements by filter hybridization and immunophenotype using FACS analysis as described above.
